(Q55467925)

12 July 2018

title

Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. (English)

1 reference

12 July 2018

0 references

0 references

Xiao-Jia Huang

1

1 reference

12 July 2018

Zhen-Qiu Ma

2

1 reference

12 July 2018

Wei-Ping Zhang

3

1 reference

12 July 2018

Yun-Bi Lu

4

1 reference

12 July 2018

Er-Qing Wei

5

1 reference

12 July 2018

publication date

1 June 2007

1 reference

12 July 2018

Journal of Pharmacy and Pharmacology

published in

1 reference

12 July 2018

volume

59

1 reference

12 July 2018

issue

6

1 reference

12 July 2018

page(s)

849-856

1 reference

12 July 2018

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Qinghaosu (artemisinin): an antimalarial drug from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Effects of artemisinin-tagged holotransferrin on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

A medicinal chemistry perspective on artemisinin and related endoperoxides

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.59.6.0011

21 January 2018

Identifiers

DOI

10.1211/JPP.59.6.0011

1 reference

12 July 2018

1 reference

12 July 2018